We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
In anticipation of proposed guidance on biosimilar interchangeability, AbbVie is requesting that the FDA hold a hearing to ensure the agency considers all viewpoints. Read More
Nearly a dozen organizations are calling for clarification on a draft FDA plan to label injectable therapies that are meant to be used multiple times by a single patient as products for “single patient–use.” Read More
In observance of the holiday season, Drug Industry Daily will not be published Thursday, Dec. 31 and Friday, Jan. 1. The next issue will be published Monday, Jan. 4. Read More
While Teva Pharmaceutical and Takeda Pharmaceutical have framed a previously disclosed joint venture in Japan as a “partnership,” new details about the arrangement show that Takeda is selling off drugs for stock. Read More
Chimerix’s Brincidofovir Falls Short in Phase 3
Court Oks PharmAthene’s $113M Award Against Siga
Valeant CEO on Medical Leave, Company Execs Take Interim Reins Read More
In the wake of the 2014 Ebola outbreak, the FDA is weighing the best options for testing and rapidly deploying treatments for emerging infectious diseases and wants to hear from you on the subject. Read More
Celgene, Natco Settle Revlimid Patent Spat
Turing to Cut Jobs, Seek New CEO in Shake-Up
DEA Relaxes Controls on Approved Cannabidiol Trials
Judge Dismisses NYU Cancer Drug Royalties Claim Against Pfizer
Adamas Compound Hits Primary Endpoint in Study
Kamada’s Rabies Candidate Meets Goal Read More
A California supplement maker is in hot water after being accused of making drug-like claims about its products and relying on improper production methods. Read More